Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye

Paul Hahn Duke Eye Center, Duke University Medical Center, Durham, NC, USA Abstract: Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy in vitrectomized eyes remains a challenge due to the reduced half-life of these agents. Aflibercept may have stronger binding activity a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Hahn P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/ac166e2228324f9db5ad66860dfbfcda
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ac166e2228324f9db5ad66860dfbfcda
record_format	dspace
spelling	oai:doaj.org-article:ac166e2228324f9db5ad66860dfbfcda2021-12-02T00:01:54ZSuccessful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye1177-5483https://doaj.org/article/ac166e2228324f9db5ad66860dfbfcda2014-10-01T00:00:00Zhttp://www.dovepress.com/successful-treatment-of-neovascular-age-related-macular-degeneration-f-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Paul Hahn Duke Eye Center, Duke University Medical Center, Durham, NC, USA Abstract: Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy in vitrectomized eyes remains a challenge due to the reduced half-life of these agents. Aflibercept may have stronger binding activity and a longer intravitreal half-life compared to bevacizumab and ranibizumab, but its use in postvitrectomy eyes has not been reported. We present a case of an 89-year-old female, with recurrent choroidal neovascularization 10 years following prior macular translocation vitrectomy surgery for neovascular age-related macular degeneration, successfully treated with monthly aflibercept injections initiated following poor response to a single initial bevacizumab injection. This report suggests that aflibercept may be an important treatment option for vitrectomized eyes requiring anti-VEGF treatment. Keywords: anti-VEGF, vitrectomized, aflibercept, neovascular age-related macular degeneration Hahn PDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 2129-2131 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Hahn P Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
description	Paul Hahn Duke Eye Center, Duke University Medical Center, Durham, NC, USA Abstract: Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy in vitrectomized eyes remains a challenge due to the reduced half-life of these agents. Aflibercept may have stronger binding activity and a longer intravitreal half-life compared to bevacizumab and ranibizumab, but its use in postvitrectomy eyes has not been reported. We present a case of an 89-year-old female, with recurrent choroidal neovascularization 10 years following prior macular translocation vitrectomy surgery for neovascular age-related macular degeneration, successfully treated with monthly aflibercept injections initiated following poor response to a single initial bevacizumab injection. This report suggests that aflibercept may be an important treatment option for vitrectomized eyes requiring anti-VEGF treatment. Keywords: anti-VEGF, vitrectomized, aflibercept, neovascular age-related macular degeneration
format	article
author	Hahn P
author_facet	Hahn P
author_sort	Hahn P
title	Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
title_short	Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
title_full	Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
title_fullStr	Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
title_full_unstemmed	Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
title_sort	successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/ac166e2228324f9db5ad66860dfbfcda
work_keys_str_mv	AT hahnp successfultreatmentofneovascularagerelatedmaculardegenerationfollowingsinglebevacizumabfailureusingafliberceptinavitrectomizedeye
_version_	1718404007020462080

Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye

Ejemplares similares